Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer.

Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer. Abstract Text:

Sebastian ,Sumito Sato,Timo Huber,Alfred Morgenstern,Frank Bruchertseifer,Manfred Schmitt,Horst Kessler,Reingard Senekowitsch-Schmidtke,Viktor Magdolen,Christof Seidl,

PURPOSE: Among gynecologic malignancies, ovarian cancer has the highest mortality due to rapid peritoneal dissemination. Treatment failure particularly arises from failure to eliminate disseminated cells. Our aim was to develop peptidic radioligands targeting tumour cell-associated urokinase receptor (uPAR, CD87) for alpha-emitter therapy for advanced ovarian cancer. METHODS: DOTA-conjugated, uPAR-directed ligands were synthesised on solid-phase. Binding of peptides to human cells expressing uPAR was assayed by flow cytofluorometry or, in case of (213)Bi-labelled peptides, by measuring cell-bound radioactivity. Bio-distribution of the (213)Bi-labelled peptide P-P4D was analysed in nude mice 28 days after intraperitoneal inoculation of OV-MZ-6 ovarian cancer cells in the absence or presence of the plasma expander gelofusine. RESULTS: uPAR-selective ligands were developed based on published high-affinity uPAR-binding peptides. For preparation of N-terminally cross-linked divalent ligands, a novel solid-phase procedure was developed. Specific binding of (213)Bi-labelled peptides to monocytoid U937 and OV-MZ-6 cells was demonstrated using the natural ligand of uPAR, pro-uPA, or a soluble form of uPAR, suPAR, as competitors. The pseudo-symmetrical covalent dimer (213)Bi-P-P4D displayed superior binding to OV-MZ-6 cells in vitro. Accumulation of (213)Bi-P-P4D in tumour tissue was demonstrated by bio-distribution analysis in nude mice bearing intraperitoneal OV-MZ-6-derived tumours. Gelofusine reduced kidney uptake of (213)Bi-P-P4D by half. CONCLUSION: Ovarian cancer cells overexpressing uPAR were specifically targeted in vitro and in vivo by (213)Bi-P-P4D. Kidney uptake of (213)Bi-P-P4D was distinctly reduced using gelofusine. Thus, this radiopeptide may represent a promising option for therapy for disseminated ovarian cancer.

Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer. Publishing Authors By Initials

S ,S Sato,T Huber,A Morgenstern,F Bruchertseifer,M Schmitt,H Kessler,R Senekowitsch-Schmidtke,V Magdolen,C Seidl,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: European journal of nuclear medicine and molecular

VOLUME: 35

Page Numbers: 53-64

Journal Abbreviation: Eur. J. Nucl. Med. Mol. Imagin

ISSN: 1619-7070

DAY: 22

MONTH: 09

YEAR: 2007

Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101140988

Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer.

AFFILIATION: Department Chemie, Lehrstuhl II für Organische Chemie, Technische Universität München, Lichtenbergstrasse 4, 85747, Garching, Germany.

Country: Germany

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Eur J Nucl Med Mol Imaging

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor uPAR for use in alpha-emitter therapy for disseminated ovarian cancer Related Publications

• A new HLA-B*08 allele, HLA-B*0828, found in two voluntary stem cell donors.
• Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer.
• Extended query refinement for medical image retrieval.
• Incidence and clinical impact of right bundle branch block in patients with acute myocardial infarction: ST elevation myocardial infarction versus non-ST elevation myocardial infarction.
• Lipid contaminants: Polypropylene apparatus and vacuum pumps.
• Long-term prognosis after cardioversion of the first episode of symptomatic atrial fibrillation: a condition believed to be benign revised.
• Performance of mentally retarded adults on the Canadian Standardized Test of Fitness.
• Response bias in "remembering" emotional stimuli: A new perspective on age differences.
• Secondary-progressive form of multiple sclerosis: MRI changes versus clinical status.
• Visualization and Quantification of the Anisotropic Effect of CC Double Bonds on (1)H NMR Spectra of Highly Congested Hydrocarbons-Indirect Estimates of Steric Strain.
• [Foetal complications associated with use of foetal scalp electrodes and scalp blood sampling (author's transl)]
• [Microwave-cured prosthesis resins. First practical experience]
• [Moore's operation in a case of fracture of the femoral neck and old epiphyseolysis of the femoral head.]
• [Not Available.]
• [Not Available.]
• [Not Available.]
• [Not Available.]
• [On the importance of papillary ovarian cystomas]
• [Possibilities and limits of medical conversation]
• [Problem of anesthesia in the diagnostic conization of the cervix]
• [Stigmatisation and absence of nutrition in the case of Therese Neumann (1898-1962).]
• [The application of the HL-A-system in cases of disputed paternity. Studies on 110 families (author's transl)]